Although solubility-pH data for desipramine hydrochloride (DsHCl) have been reported previously, the aim of the present study was to critically examine the aqueous solubility-pH behavior of DsHCl in buffer-free and buffered solutions, in the presence of physiologically-relevant chloride concentration, using experimental practices recommended in the recently-published "white paper" . The computer program pDISOL-X was used to design the structured experiments (pH-RSF method), to process the data, and to refine the equilibrium constants. Low-to-high and high-to-low pH assays (using HCl, H 3 PO 4 , or NaOH to adjust pH) were performed on phosphate-buffered (0.12-0.15 M) saturated solutions of DsHCl in the pH 1.3-11.6 range. After equilibration (stirring 6 h, followed by 18 h stir-free sedimentation), filtration or centrifugation was used for phase separation. Concentration was measured using HPLC with UV/VIS detection. . Under the assay conditions, only the phosphatefree solutions showed some supersaturation near pH max 8.0. In phosphate-containing solutions, pH max was indicated at higher pH (8.8-9.6). Oils mixed with solids were observed to form in alkaline solutions (pH > 11). Notably, soluble drug-phosphate complexes appeared to form below pH 3.9 and above pH max in saturated phosphate-containing saline solutions. This was indicated by the systematic pH shift to higher values in the log SpH curve in alkaline solution than expected from the Henderson-Hasselbalch equation. For pH < 3.9, saturated phosphate-containing saline solutions exhibited elevated solubility, with drug-hydrochloride as the sole precipitate. Salt solubility products, intrinsic solubility, and complexation constants, which rationalized the data, were determined. Elemental, thermogravimetric (TGA), differential scanning calorimetric (DSC), and powder Xray diffraction (PXRD) analyses were used to characterize the precipitates isolated from suspensions at different pH.
Introduction
Amphiphilic tricyclic bases, such as dibenzazepines and phenothiazines, are surface-active, sparingly-soluble drugs, which can exhibit complicated aqueous solution chemistry. Many of the drugs in free-base form have low melting points (Bradley et al., 2018) . In highly alkaline solutions, these drugs sometimes separate out of solution as oil, with elevated solubility. Surface-active drugs often form supersaturated solutions near the salt-to-free-base transition pH (pH max ), where partially-charged sub-micellar or micellar aggregates form (Higuchi et al., 1953; Zografi et al., 1964; Zografi and Zarenda, 1966; Sorby et al.,Streng, 1996; Attwood et al., 1997; Ledwidge and Corrigan, 1998; Gebauer et al., 2014) .
The above drugs precipitate over a wide range of pH, forming solids in contact with dissolved monomers, and often, also with water-soluble sub-micellar aggregates (e.g., dimers, trimers, and higher-order oligomers). Attwood et al. (1974) found that distilled water solutions of promazine and chlorpromazine hydrochlorides form small micelles in aggregated units of eleven monomers. Zografi and Zarenda (1966) noted that a 2-5 μM (below solubility limit) solution prepared from chlorpromazine free base (pH 9-12) showed no surface activity. However, a 30 μM hydrochloride solution at pH 9 produced a stable supersaturated solution, which partly separated as oil (liquid-liquid phase separation, LLPS) and was more soluble than the crystalline free base. The above operationally non-commutative solubility behavior may be further influenced by complexation/hydrotropy reactions, depending on the buffer used (Shoghi et al., 2013) .
The earliest measurement of the intrinsic solubility (S 0 ) of desipramine appears to be that of Green (1967) , who reported log S 0 = −3.66. More recently, a buffer-free potentiometric method was used to determine the intrinsic solubility of desipramine as log S 0 = −3.81 (Bergström et al., 2003) . Also, both the log S 0 -3.69 and the pK a 10.28 values were simultaneously determined using the pSOL (Pion Inc.) buffer-free method (Avdeef, 2012) . A small-scale shake-flask solubility measurement of desipramine hydrochloride in the pH range of 1.4 to11.2 in 0.15 M phosphate solution revealed a curve that did not adhere to the shape predicted by the simple Henderson-Hasselbalch (HH) equation (Bergström et al., 2004) . When the HH equation was applied to the point at pH 11.2, log S 0 = −3.90. On the other hand, a sigmoidal fit of the data in the alkaline region suggested log S 0 = −3.37. The observed log S-pH slope in the diagonal region was reported as −0.6, whereas −1 would have been expected from the HH equation. Since the lower inflection in the fitted curve was near pH 7.5, well below the pK a , an alternative model based on putative aggregation of the free base indicated log S 0 = −6.40 (Avdeef, 2014b) , a value very different from those of all the other studies. Solid state characterizations to identify the solids isolated from suspensions at various pH were not reported in the above studies. The solution behavior of desipramine in phosphate-buffered and unbuffered solutions is evidently complicated and only tentatively understood, given the above incongruities.
The aim of the present study was to critically re-examine the aqueous solubility-pH behavior of desipramine hydrochloride (DsHCl) in phosphate-buffered and buffer-free solutions, in the presence of physiologically-relevant chloride concentration. Specifically, solubility was measured: (a) using state-of-the-art experimental design, as recommended in a "white paper" on solubility , drawing on expert consensus opinions from researchers in six countries; (b) performing solubility titrations in two directions, pH 11.6→1.3 as well as 1.3→11.6; (c) using both DsHCl and Ds (free base), as starting solids; (d) performing titrations in chloride-containing media, without any phosphate; (e) performing the converse measurements (phosphatecontaining, chloride-free media); (f) isolating solids at critical log S-pH points and performing solid state characterizations using elemental, thermogravimetric, differential scanning calorimetric, and powder X-ray diffraction analyses. The recently-developed computational methods were applied to determine aggregation and/or complexation constants and stoichiometries from solubility-pH data (Avdeef, 2007 (Avdeef, , 2012 Völgyi et al., 2013; Avdeef, 2014a Avdeef, , 2014b Butcher et al., 2015; Pobudkowska et al., 2016; Takács-Novák et al., 2017) . We sought to determine the solubility products K 
Materials and methods

Chemicals and reagents
Desipramine hydrochloride (DsHCl) and sodium dihydrogen phosphate dihydrate (analytical reagent grade) were purchased from SigmaAldrich and used as received. Hydrochloric acid and sodium hydroxide were purchased from Merck (Titrisol® ampoules). Phosphoric acid (analytical reagent grade) was purchased from Fisher Chemical. All solutions were prepared with Millipore-purified water.
pH measurement
In all experiments, pH values were measured using Crison pHBurette 24 2S equipped with a micro-combined pH electrode (Crison pH electrode 50 29). The electrode was calibrated by standard Crison buffer solutions (pH 4.01, 7.00, and 9.21).
HPLC concentration determination
After equilibration in the solubility experiments, excess solid was removed by filtration or centrifugation (cf., Supplementary material). The concentration of the drug in the supernatant was determined by HPLC-UV/VIS system (Agilent Technologies 1260 Infinity LC System). Chromatographic separation was conducted using Zorbax Eclipse XDB-C18 50 × 4.6 mm column with 1.8 μm particles at flow rate of 0.5 mL/ min. Gradient elution was used: from 70% A + 30% B to 100% B during 5 min, 100% B for 1 min, and back to 70% A + 30% B during 1 min (solvent A: water with 1% acetic acid; solvent B: acetonitrile). Detection wavelength: 250 nm; column temperature: 25°C.
Differential scanning calorimetric (DSC) analysis
Solids isolated from suspensions were analyzed for their thermal behavior as a function of temperature using a Q200 differential scanning calorimeter (TA instruments, DE, USA). Samples (5-10 mg each) were sealed in Tzero pan with a pinhole for the escape of any volatile material. The samples were equilibrated at 5°C for 5 min and then heated at the rate of 10°C/min to the final temperature of~225°C that was above the potential melting points of samples. When heat-cool-heat cycles were used, samples were prepared similarly and then initial heating, cooling and reheating were conducted at rates of 10, 30 and 3°C/min; the reheating was done at a lower heating rate to facilitate any recrystallization of material. The results were analyzed using Universal Analysis software version 2000 (TA Instruments).
Thermogravimetric analysis (TGA)
Approximately 4-6 mg of samples were analyzed using the TGA Q50 thermogravimetric analyzer, (TA instruments, DE, USA). The samples were heated from~25°C to 300°C at a heating rate of 10°C/min in a nitrogen environment.
Powder X-ray diffraction (PXRD) analysis
A powder X-ray diffractometer (Shimadzu 6000, Kyoto, Japan) was used to obtain PXRD patterns at room temperature with a monochromatic CuKα radiation source operated at 40 kV and 30 mA and the scanning rate of 2°/min over the 2θ range of 10°to 60°. The test materials were placed as thin layers inside glass sample holders.
Elemental analysis
The elemental analysis was accomplished by combustion analysis on a Vario EL III C,H,N,S/O Elemental Analyzer (Elementar Analysensysteme GmbH, Hanau-Germany).
Solubility determination using the pH-Ramp Shake-Flask (pH-RSF) method
Before commencing any assays, solubility-pH simulations were performed using the computer program pDISOL-X™ (in-ADME Research). This was to plan for the weights of reagents to use (including buffers, if suggested), as well as the expected volumes of titrants to add in order to adjust the pH to suitable spacing (e.g., 0.2-0.5 units) across the whole pH range of interest. Knowledge of the drug pK a value and an in silico estimate of the intrinsic solubility, S 0 , are essential. Also, in the case of phosphate-containing media, drug-phosphate solubility products (K sp ) can be approximated from the S 0 values (Avdeef, 2014b) . For other counterions, the sdiff 3-4 approximation (Avdeef et al., 2000) may be used if the ionic strength is near~0.15 M. The pK a values of most common buffers, as a function of temperature and ionic strength, are encoded in the computer program used to design assay. Ordinarily, buffers are only recommended when pH adjustment cannot be precisely controlled by additions of standardized strong acid (e.g., HCl) or strong base (e.g., NaOH) titrant. The conversion of pH electrode reading from the "operational" scale to the concentration scale was effected by a four-parameter calibration procedure (Avdeef and Bucher, 1978; Avdeef, 2012) . The experiments conducted here were guided by the above ("think-before-leap") procedure, which we call the pH-Ramp Shake-Flask (pH-RSF) method.
By contrast, traditional procedures are often trial-and-error in staging the collection of data. A series of buffers is selected to cover a range of pH suitable for the study. Phosphate, acetate, and borate buffers are commonly selected, often at 50-100 mM concentration. Solid compound is added incrementally to a solution buffered at a desired pH until an unspecified "excess" solid remains undissolved. In some cases, the procedure significantly alters the initial pH of the solution, requiring adjustments by additions of a strong acid or base. Sometimes, the buffer constituents form complexes with the drug (Shoghi et al., 2013) , raising the equilibrium solubility. Also, buffer constituents may act as counterions leading to drug-salt precipitation, lowering the equilibrium solubility. Some buffers interfere with the analytical methods used to determine drug concentration (e.g., phosphate buffers in mass spectrometry). Assay details are often inadequately documented in traditional studies.
Tables S1-S3 given in Supplementary material summarize in sufficient detail the initial compositions and experimental conditions used in the solubility experiments. The temperature was kept constant at 25 ± 1°C. Titrant solutions of HCl, NaOH, and H 3 PO 4 were nominally 1 M, with precise concentrations determined potentiometrically.
Sets 1 and 2 (high-to-low pH titration replicates)
Titrations were performed in two directions: high-to-low pH values (Sets 1 and 2) and low-to-high pH (Set 3). Sets 1 and 2: alkaline stock solutions were prepared by mixing 39.5 mL of 0.15 M NaH 2 PO 4 (pH 4.34-4.37) and 10.5 mL standardized 1 M NaOH. DsHCl was added directly to the stock solutions: 0.41170 g (Set 1) and 0.41220 g (Set 2). Two-milliliter aliquots of the well-mixed drug-containing saturated stock suspensions were placed into each of 13 vials. The initial pH in the vials was 11.5-11.6. To each vial, a pre-calculated different volume of standardized 1 M HCl was added, ranging from 0 to 410 μL. The vials were capped and stirred for 6 h. After that, stirring was turned off, and sedimentation was allowed to take place for a further 18 h ("6 + 18 h" agitation-sedimentation equilibration sequence suggested in the "white paper"). All solids in the suspensions dissolved below pH 4.
Set 3 (low-to-high pH titration)
The Set 3 acidic stock solution was prepared by mixing 14.0 mL of 0.15 M NaH 2 PO 4 (pH 4.45) and 1.00 mL standardized 1 M HCl. To the stock solution, 0.34370 g of DsHCl was added. A 1-mL aliquot of the well-mixed stock suspension was placed into each of 11 vials. To each vial, a different volume of standardized 1 M NaOH was added, ranging from 80 to 370 μL. The vials were capped and agitated as before ("6 + 18 h"). Below pH 4, no solids were found to precipitate in the vials.
Set 4 (raised concentrations)
Set 4 was designed to force precipitation in the pH 2-4 region. In the experiments, 0.900 mL of 0.15 M NaH 2 PO 4 solution was added to each of three vials containing 0.08650-0.08730 g DsHCl. The pH was adjusted using 1 M H 3 PO 4 (Samples 1 and 2), NaOH (Sample 2), or HCl (Sample 3). The vials were capped and the solutions were allowed to equilibrate as before ("6 + 18 h"). Phases were separated by centrifugation (Samples 1 and 2) or filtration (Sample 3).
Set 5 (phosphate-free titrations)
A set without phosphate buffer was also designed (Set 5) in order to determine the drug-hydrochloride solubility product in phosphate-free suspensions. Precisely 1.00 mL of 0.15 M NaCl was added to each of 7 vials containing accurately-weighed 0.04745-0.11205 g of DsHCl. The pH was adjusted with standardized HCl (1.0211 M) and/or standardized NaOH (1.0215 M). Stirring was followed by sedimentation ("6 + 18 h"). Equilibrated pH values ranged from 1.31 to 10.04. Phases were separated by centrifugation.
The detailed titration and solubility data are summarized in Tables  S4-S8 (Supplementary material).
Preparation of samples for solid state characterization
The above five titration sets did not produce sufficient amounts of solid for further analysis. So, in order to characterize the solid precipitate found in samples after equilibration, two series of additional experiments (below) were performed at pH expected to contain a specific single solid form of the drug, as suggested by preliminary analyses of the above five titration sets.
Series 1 (samples OM11-OM15, from suspensions containing both chloride and phosphate)
Precisely 2.00 mL of 0.15 M NaH 2 PO 4 solution were added to 5 vials containing accurately weighted 0.14-0.18 g of DsHCl. The total drug concentrations were about 2-3 times higher than those of Set 3. The pH was adjusted with 1 M HCl or NaOH. The vials were capped and allowed to equilibrate ("6 + 18 h"). Phases were separated by centrifugation, and each solid was further analyzed. The assay design details are summarized in Table S2 (Supplementary material).
Series 2 (samples OM21-OM25, with one solid isolated from chloride-free suspensions)
Sample OM21 was prepared in two steps. (a) To isolate the free base: precisely 2.00 mL of 0.15 M NaH 2 PO 4 solution were added to 0.125 g of DsHCl and mixed with 650 μL of 1 M NaOH. The sample was stirred for 6 h and left to sediment for 62 h. Despite longer sedimentation time at pH 11.6, precipitate was still oily. Phases were separated by centrifugation. Solid Ds (free base) was left to dry. (b) 900 μL of 0.15 M NaH 2 PO 4 solution were added to 0.096 g of Ds precipitate from step (a) and mixed with 400 μL of 1 M H 3 PO 4 . The low-pH suspension was allowed to equilibrate ("6 + 18 h"). Phases were separated by centrifugation. The OM21 solid was washed with purified water and left to dry.
Samples OM22-OM25 approximately paralleled the compositions in Set 3, except that 2-3 times higher drug concentrations were used. The specific quantities of reagents used are summarized in Table S3 (Supplementary material). Equilibration followed the "6 + 18 h" procedure. The solids were separated from the suspensions by centrifugation, washed with purified water, and allowed to dry in air.
Refinement of intrinsic and salt solubility, aggregation and complexation constants
The mathematical approach used in the pDISOL-X log S-pH simulation-refinement has been described by Völgyi et al. (2013) . The program has been applied in several other recent studies (Avdeef, 2014a (Avdeef, , 2014b Butcher et al., 2015; Avdeef, 2015; Pobudkowska et al., 2016; Takács-Novák et al., 2017) . Briefly, the data analysis method uses log SpH as measured input data, with concentrations determined by a suitable analytical technique. The analytical concentrations of all added reagents are specified. "Excess drug added" is not sufficient information when drug-phosphate salts are suspected to precipitate during the titration, as emphasized in the "white paper." The mass action algorithm considers the contribution of all species proposed to be present in solution, including all buffer, counterion, and inert electrolyte components. The approach does not assume the validity of the HendersonHasselbalch relationship, nor does it depend on any explicitly derived extensions of the HH equations. The mass action algorithm derives its own implicit equations internally, given any practical number of hypothesized equilibrium reactions and the corresponding estimated constants, which are subsequently refined by weighted nonlinear leastsquares regression. The presence of specific drug-phosphate precipitates can be tested. The program calculates the distribution of species consequent to a sequence of additions of standardized strong-acid titrant HCl (or ionizable-acid titrants such as H 3 PO 4 ) to simulate the suspension pH-speciation down to pH~0, the staging point for the subsequent steps. Then, a sequence of perturbations with standardized strong-base titrant (e.g., NaOH) is simulated, and solubility calculated at each point, until pH~13 is reached. The ionic strength, I, is rigorously calculated at each step, and the pK a value (as well as solubility products, aggregation and complexation constants), along with pH electrode calibration constants, are accordingly adjusted for changes from the benchmark level of 0.15 M (Avdeef, 1992 (Avdeef, , 2012 .
At the end of the pH-speciation simulation, the calculated log S-pH curve is compared to measured log S vs. pH. A user-supervised log Sweighted nonlinear least squares refinement commences to refine the user-proposed equilibrium model. The underlying differential equations are solved using analytical expressions encoded in the program. The process is repeated until the differences between calculated and measured log S values reach a minimum. Different model species are tested to make further improvements in the fit.
Results and discussion
Summary of the interlaboratory consensus recommendations applied in this study
The "white paper" commentary ) reviewed a number of factors that can affect the quality of equilibrium solubility measurement as a function of pH of sparingly-soluble druglike molecules. It was asserted that the traditional shake-flask method is the "gold standard," although other validated methods with well-defined protocols could also be used. It was stressed that independently-determined pK a values of the drug be used in the analysis of the log S-pH data. The importance of solid state characterization was also stressed, citing several case studies of polymorphic transformations. The complexity on the solution side of solubility-pH measurement was illustrated with several case studies, where aggregates (micellar and submicellar) and drug-buffer complexes appeared to form. The importance of measuring the final pH (not that of the starting buffer) accurately in buffered and unbuffered solutions was discussed at length. Methods and pitfalls of separating solid from saturated solutions were critically discussed. The reporting of the temperature, ionic strength, buffer compositions, and other experimental detail was encouraged. When such "good practices" could be followed, it was expected that high quality results in solubility measurement could be achieved.
pK a determination from solubility-pH data
The independently measured pK a of desipramine, 10.28 ± 0.03 (26°C, I ref 0.15 M), verified by three different potentiometric procedures (Avdeef, 2012) , was used in the study here. The apparent constant determined from the current log S-pH data led to values as high as 10.44. The significant difference between the two values led us to suspect that either aggregation or complexation reactions may be present in the phosphate-containing alkaline solutions.
Solubility analysis
Data
The solubility-pH profiles of DsHCl in buffer-free and phosphate buffer, designed with the pH-RSF method, are shown in Fig. 1 . The reported solubility values are based on molarity units. The detailed titration (V titrant -pH) and solubility (log S-pH) data are presented in Tables S4-S10 (Supplementary material).
Sets 1 and 2 (Fig. 1a) are duplicate experiments, where alkaline suspensions (pH 11.6) containing [Ds] tot = [Cl] tot = 27 mM and [PO 4 ] tot = 119 mM, were acidified with HCl. Set 3 (Fig. 1b) represents the titration in the opposite direction, where acidified (pH 1.90) suspensions, with somewhat higher concentrations [Ds] tot = 76 mM, [Cl] tot = 142 mM, and [PO 4 ] tot = 140 mM, were titrated with NaOH up to pH 11.6. In the three sets, solutions below pH 3.9 did not achieve saturation.
Set 4 (upper Fig. 1c ) was designed in order to get solid precipitate in pH region below 4. Higher drug concentrations were used:
[Ds] tot = [Cl] tot = 320 and [PO 4 ] tot = 150 mM. The number of analyzed samples in this pH region was limited due to excessive amounts of DsHCl required to reach saturation.
Due to the possibility of co-precipitation of chloride and phosphate drug salts at low pH (Völgyi et al., 2013) , the phosphate-free Set 5 (lower Fig. 1c) Table  S8 ).
Series 1 and 2 measurements (cf., Tables S2, S3 , S9, and S10) were designed in order to get enough precipitate for solid state analysis.
Refinement of constants
Whereas the solubility product is an equilibrium constant, the solubility of a charged drug is variable, whose value depends on the concentration product of two independent reactants (drug and counterion). In the pH domain where the drug is charged, its solubility can be varied simply by selecting different concentrations of the counterion. The "common ion" effect of a drug hydrochloride salt is a good example of this phenomenon: the solubility of a positively-charged drug decreases as HCl is used to lower the pH (which increases the chloride counterion concentration).
The sample points from each of Sets 1-5 were designed (pH-RSF) specifically to be fit to a single log S-pH curve across a range of pH values, generally requiring that for each sample point, the total drug concentration (after correction for dilution) to be essentially the same, and that the drug:counterion ratio to be variable only when the titrant includes the counterion as a constituent. On the other hand, the Series 1 and 2 sets (Samples OM11-15 and OM21-25) were less constrained as they were designed to generate sufficient quantities of precipitate for solid state characterizations, with different samples possibly associated with different members of a conditional family of log S-pH curves.
The determination of equilibrium constants began with Sets 1 and 2 treated separately. Since nearly the same constants were determined by weighted nonlinear regression, the two sets were merged, and a combined analysis was performed. The refined constants are summarized in Table 1 and the plot of the fitted curve is shown in Fig. 1a by the solid curve. The dashed curve in the figure was calculated with the 1 . Solubility-pH profiles for the desipramine at 25°C. The dashed curves were calculated with the Henderson-Hasselbalch equation, using the independently-determined pK a = 10.28 and the intrinsic solubility log S 0 = −3.85, determined from Set 5 (cf., Table 1 4 ] tot = 150 mM. Set 5 (lower curve) consisted of buffer-free 0.15 M NaCl suspensions of DsHCl, with HCl/NaOH to adjust the pH. The data in Set 5 were used to determine the drug-hydrochloride solubility product in phosphate-free suspensions, and to determine the intrinsic solubility, log S 0 , in the absence of phosphate complexation.
Henderson-Hasselbalch (HH) equation, using the independently-determined pK a 10.28. It is evident in Fig. 1a for pH > pH max (a conditional constant) that the points do not fall on the HH curve. In certain cases, the pK a value can be determined from the solubility data. However, in our case the resultant value was significantly higher than the independently-determined pK a . In complicated systems, it is not recommended that the pK a value be determined from log S-pH data (Butcher et al., 2015; Völgyi et al., 2010) . At least two possible explanations for the difference could be proposed here: (a) drug self-aggregation (e.g., dimer formation), or (b) drug-buffer complexation (e.g., Ds-phosphate anionic complexes). Since the analysis of Set 5 (lower Fig. 1c) did not indicate deviations from the HH curve in the alkaline solution, drug-phosphate complexation (b) was favored over drug selfaggregation (a). The data were tested against several possible complexation reactions. The simplest which rationalized the data was based on the reaction involving the formation of a monoanionic complex, 
where the superscript 2:1 refers to the drug:phosphate stoichiometry of the formed solid. The refined value is log K sp 2:1 = −7.38 ± 0.01 (Table 1) . Since the solutions in Set 1 and 2 contained chloride, it was necessary to verify that the solubility product was due solely to reaction (2a). Set 5, which contained no phosphate, indicated that the drugchloride solubility product is log K sp DsH % Cl = −2.19 ± 0.03 (Table 1) .
When this value was included in the equilibrium model for Sets 1 and 2, along with the other constants, it was found that the solubility product for the hydrochloride salt was not exceeded, so no hydrochloride salt co-precipitate was expected at the concentration levels in Sets 1 and 2 (pH > 4). The intrinsic solubility, log S 0 = −3.85, was entered in the Sets 1 and 2 refinement as a fixed contribution, based on the value refined with the Set 5 data, which showed no deviations from the HH curve. It would be challenging to refine both the log S 0 and the log K 221 simultaneously in Sets 1 and 2, since the two constants are co-dependent.
Since the tendency to form a supersaturated solution (often near pH max ) depends on the solid state of the starting materials (e.g., Zografi and Zarenda, 1966) , Set 3 was devised to be a titration going from lowto-high pH, in the direction opposite of that of Sets 1 and 2. Fig. 1b shows the best-fit results of the analysis. In the alkaline solution of Set 3, there is comparable deviation from the HH curve, as in the case of Sets 1 and 2. Table 1 lists the refined constants. The salt solubility was somewhat elevated in Set 3, compared to that in Sets 1 and 2. The complexation constants were slightly different, but not significantly, given the standard deviations, SD = 0.10, from the refinement in both cases. The measured solubility values of samples OM14, OM15, OM24 and OM25 were merged into the Set 3 calculations, since these OM samples were at pH > pH max (cf., Fig. 1b) , where salt precipitation is minimal. The OM samples were also consistent with complexation taking place.
As evident from the above discussion, the phosphate-free Set 5 data analysis played a key role in rationalizing the phosphate-containing model based on the Sets 1-3 data. Set 5 data were taken to be an accurate basis for the determination of the intrinsic solubility of desipramine: log S 0 = −3.85 ± 0.04, in the apparent absence of interference due to complex formation.
Set 4 (upper curve in Fig. 1c ) also played an important role in the evolution of the overall equilibrium model. The low pH and the high drug concentrations suggested that both DsH·Cl and DsH·H 2 PO 4 could co-precipitate, since the log K sp , −2.19 (from Set 5) and −2.55 (from Sample OM21), respectively, were comparable. However, the inclusion of both constants in the data analysis could not explain the upper curve in Fig. 1c . It was only after the formation of a monocationic complex was included that the fit was possible.
with the corresponding constant (3b)
The refined value is log K 241 = 3.96 ± 0.02 (Table 1) . A further unexpected subtlety was revealed (supported by DSC measurement below): even though the K sp of DsH·H 2 PO 4 (s) was lower than that of DsH·Cl(s), under the concentrations in Set 4 samples, it was the hydrochloride salt that precipitated. The solubility product of the phosphate salt was below the equilibrium constant value, partly because the phosphate was preferentially tied up with the water-soluble monocationic complex. The discussion in Section 3.4.2 further elaborates on this.
Desipramine solid state characterizations
Elemental analysis
Elemental analysis (EA) results are shown in Tables 2 and 3 . The CHN analysis of the reference (Sigma-Aldrich) DsH·Cl(s) solid was 70.89% C, 7.46% H, 9.20% N. Evidently, the solids isolated from Set 5 (phosphate-free) from pH 1.3-7.5 suspensions are likely the anhydrous DsH·Cl(s) ( Table 2 ). The solids isolated from phosphate-containing suspensions (Table 3 ) have less obvious identities based on the elemental analyses. As a guide, the comment column in Table 3 lists the species suggested from the pHspecific PXRD analyses (below). Based on theoretically-calculated CHN percentages, most of the samples appear to be extensively hydrated (or not adequately dried). Sample OM15 (pH 11.1) is compatible with Ds.2H 2 O, while OM14 (pH 9.57) and OM24 (pH 9.44) are more concordant with Ds.6H 2 O. The samples in the pH 3.84-8.55 interval are compatible with hydrates of the 2:1 phosphate salt: from 4-hydrate (OM12) to 16-hydrate (OM23). EA of OM21 is consistent with a dihydrate of the 1:1 phosphate salt. However, the TGA data (Fig. 2) indicates lower levels of hydration than that of EA, although the trends between the two types of assessments are similar. The equilibrium analysis of the log S-pH data, consistent with the constants reported in Table 1 , suggests that at pH 9.44 and 9.58, the only solid present in the Fig. 2 . Thermogravimetric analysis (TGA) scans of precipitates obtained at different pH. Samples were used 'as is' and the moisture loss could vary depending on how the samples were isolated and dried. While the weight loss equilibrated after dehydration of samples obtained at pH 2.13, 7.41, and 8.03 (relatively flat region > 100°C), the weight loss continued in pH 9.44, 9.47 and 11.10 samples, possibly due to both dehydration and sublimation of materials. Temperatures at relatively flat regions were used to calculate weight losses in different scans. suspension is the free base. The above suggests that the phosphate salts may have a high tendency to precipitate in mostly hydrated forms. A well-known characteristic of drug-free sodium phosphate salts to be highly hydrated (up to dodecahydrate) may have spilled over into drugphosphate salts.
Solid state analyses of precipitates obtained at different pH
Results of DSC analyses of precipitates as well as the neat DsHCl (Sigma-Aldrich) are shown in Fig. 3 . All samples except for DsHCl and the precipitate obtained at pH 2.09 from the chloride-free solution showed broad endotherms at around 100-120°C in DSC scans (OM12, OM13, OM14, OM23, OM24, OM25, OM15, and OM21). The results of thermogravimetric analyses (TGA) presented in Fig. 2 show that the endotherms observed at 100-120°C are apparently due to the formation of hydrates since there were weight losses in the approximately similar temperature; the onset of weight loss in TGA scans was at somewhat lower temperature due to the effect of nitrogen purging during the experiments. The presence of endotherms in the DSC scans at around 100°C and the weight loss in the TGA scans at temperatures close to 100°C indicate that any moisture associated with the solid is bound, possibly, as part of the crystal lattice or embedded deep into crystal channels (cf., Table 3 ). The PXRD patterns of the precipitates presented in Fig. 4 indicate that all the precipitates are also crystalline, although an amorphous halo was observed in PXRD patterns in one of the two precipitates isolated at pH 11.10. As shown by the DSC heat-cool-heat cycle of a representative sample (OM13) in Fig. 3d that once a sample is heated beyond its dehydration endotherm, it converts to the amorphous form unless there was a separate endotherm originally present in the sample at higher temperature (see Fig. 3a and b for sample OM21).
Although the crystalline nature of the precipitates obtained from phosphate buffered solutions at different pH cannot be readily distinguished by the DSC scans as most of them have similar dehydration endotherms at around 100°C, distinct differences exist in their PXRD patterns. As shown in Fig. 4 , there are three different PXRD patterns at (a) pH 11.1, (b) pH 9.44-7.41 and (c) pH 2.13; any minor difference observed in the range of pH 9.44 to 7.41 could be due to the difference in hydration of the crystals. These three distinctly different PXRD patterns may be attributed to the existence of, respectively, (a) Ds (free base), (b) (DsH + ) 2 HPO 4 2− (s) and (c) (DsH + )H 2 PO 4 − (s). The formation of these species agree with the ionization of phosphoric acid, which has pK a values of 1.92, 6.70, and 11.72 (25°C, I = 0.15 M) . It is evident from Fig. 3a that the free base and (DsH + ) 2 HPO 4 2− (s) exist in crystalline states only as hydrates and they convert to the amorphous phase after dehydration. On the other hand, although a hydrate, (DsH + )
H 2 PO 4 − (s) (pH 2.13) maintains its crystallinity after dehydration (Fig. 3b) . Since the solids remain in equilibrium with water during the Fig. 3 . Differential scanning calorimetric (DSC) scans of different precipitates isolated during the determination of solubility-pH profile of desipramine HCl. (a) DSC scans of precipitates and the neat desipramine HCl ('as is') as a function of temperature, indication dehydration endotherms around 100°C and melting endotherms at higher temperature; (b) heat-cool-heat run cycles of precipitate isolated at pH 2.13 (OM21), indicating dehydration in cycle 1 and only the melting peak and no dehydration during reheating in cycle 3; (c) heat-cool-heat run cycles of precipitate isolated at pH 3.86 (OM12), indicating dehydration in cycle 1 and no dehydration or melting peaks during reheating in cycle 3; and (d) heat-cool-heat run cycles of precipitate isolated at pH 7.41 (OM13), indicating dehydration in cycle 1 and no dehydration or melting peaks during reheating in cycle 3.
determination of pH versus solubility profile, these results demonstrate that the solids always remain in the crystalline state during solubility studies.
In Fig. 3a , sample OM11 ("phosphate-poor") shows an endotherm that matches that of the reference DsHCl (Sigma-Aldrich) at 217°C. It may appear surprising that OM11, consisting of 0.14 M total phosphate concentration (Table S2) ], whose concentrations is calculated to be 0.11 M. There is simply not enough uncomplexed monohydrogen phosphate available to form the drugphosphate salt under these conditions. The DSC confirms the above equilibrium analysis.
Sample OM21 ("chloride-free" in Fig. 3a) at pH 2.13 was prepared from the desipramine free base, so the endotherm at 175°C (the second dip in the DSC scan in Fig. 3a) is likely that of the melting point of the 1:1 desipramine phosphate salt. Fig. 3b shows the heat-cool-heat cycle, where the first endotherm disappears, and a sharpened dip at the higher temperature persists, suggesting a dehydration process of the 1:1 phosphate salt.
In samples OM12 and OM22 (pH 3.9), the monoanionic phosphate is near that of the total phosphate concentration, so the expected solid should not contain any chloride salt, based on the equilibrium analysis. The transition pH from (DsH)·H 2 PO 4 (s) to (DsH) 2 ·HPO 4 (s) is estimated to be at pH max between 4.0 (Fig. 1a, and b ) and 4.7 (upper curve in Fig. 1c) , depending on total concentrations used. The DSC scan of one of these samples isolated at pH 3.9 (OM12) in Fig. 3a show only the dehydration endotherm around 100°C indicating hydrate formation, and when the heat-cool-cycle was conducted, the material converted to amorphous upon dehydration (Fig. 3c) . In this respect, the sample OM12 behaves like OM13 (pH 7.4) (Fig. 3d) , which has been attributed to the formation of a 2:1 phosphate salt. Since the DSC scan of OM12 differs from that of OM21, which, as mentioned later, is considered to be a 1:1 phosphate salt, it is very likely that a 2:1 phosphate salt was formed from the buffered solution at pH 3.9. The similarity in crystal patterns between Samples OM12 and OM13 could, however, not be confirmed by PXRD as the isolated sample of OM12 was insufficient to run a PXRD experiment.
It may be noted in Fig. 4 that PXRD patterns of two precipitates isolated at pH 11.1 differ considerably with respect to their degree of crystallinity, one showing larger amorphous halo than the other. Although we are not aware of any previous study of the solid state properties of desipramine free base, they could be similar to physicochemical attributes of a related compound, chlorpromazine free base, which is known to be amorphous in the solid state (Zografi and Zarenda, 1966) . It is evident in Fig. 4 that the material isolated from aqueous medium at pH 11.1 is a crystalline hydrate that can readily convert to the amorphous form during preparation (hence the difference in amorphous halo) or upon heating. It may also be noted from the TGA scans in Fig. 2 that the free base is volatile as the sample continues losing weight after dehydration.
In contrast to precipitates isolated from the phosphate-buffered solutions, the sample OM11 (pH 2.09) that was isolated from the phosphatepoor solution showed a melting endotherm only at 217°C, indicative of the formation of anhydrous DsH·Cl, which is precisely what was predicted from the refinement of log S-pH data in Set 4. On the other hand, the chloride-free OM21 (pH 2.13) showed two melting endotherms; one around 100ᵒC and other around 175ᵒC. This is indicative of the 1:1 phosphate salt showing a dehydration pattern. Once the sample was subjected to heat-cool-reheat cycle by first heating the sample to 120ᵒC for dehydration, the first endotherm disappears and the second endotherm due to the melting of the sample becomes even sharper, indicating the high crystallinity of the 1:1 drug-phosphate salt (Fig. 3b) .
The elemental analysis of phosphate containing preparations shown in Table 3 and the TGA scans of the same in Fig. 2 show that there were different amounts of water present in different samples. As mentioned under Materials and methods, the samples were only air-dried before analysis. No further treatment was done to maintain the sample closely similar to what were present in equilibria with aqueous media. However, it is possible that all samples did not dry to the same extent during air-drying depending on how much solid was present in a wet mass and how long it was dried. Although the difference in water content did not change the nature of DSC scans and the powder X-ray patterns, it could be responsible for the observed difference in moisture content in elemental analysis and TGA scans. To investigate this possibility, we subjected samples OM13 (7.41) and OM23 (pH 8.03) that showed, respectively, 5.3 and 25.7% weight loss, to identical humidity conditions of 50% RH at 25°C by using a VTI SA dynamic vapor sorption instrument (TA Instruments, Wilmington, DE) for equilibration until there was no weight gain or loss due to moisture sorption or desorption. As shown in Fig. S1 (Supplementary materials) , there was~2% moisture sorption by OM13 (Fig. S1c) , while there was a moisture desorption of 17% with OM23 (Fig. S1a) . TGA scans of the samples equilibrated at 25°C/50% RH showed the weight loss of both samples were similar and in the range of 5-6% (Fig. S1b and d) , corresponding to approximately 2 mol of water. Thus, it is evident that the difference in moisture contents observed in Table 3 and Fig. 2 could be due to the difference in the extent of drying. However, DSC scans and PXRD patterns of various samples show that any difference in moisture content did not change crystalline nature of the precipitates formed in equilibria with phosphate buffers, and, as evident from the representative examples in Fig. 3c and d , irrespective of the extent of hydration, any (DsH + ) 2 HPO 4 2− hydrates formed may convert to amorphous form upon dehydration by heating.
Conclusions
The critical analysis of the desipramine system in saturated aqueous saline phosphate buffer suspensions revealed complexity not addressed previously.
While most pH versus solubility studies of free bases are conducted by adjusting pH by using a monoprotic acid like HCl, a triprotic acid H 3 PO 4 was used in the present study to determine the solubility-pH profile of 1:1 desipramine phosphate salt. The results are compared with the solubility-pH profile of the 1:1 desipramine chloride salt determined in a phosphate-free medium. The results showed the complex nature of the solid phase formed under different pH conditions in the phosphate buffer. At pH 11, the crystalline hydrate of the desipramine free base was formed and existed as the solid phase. At lower pH in the range of 4 to 9.5, the solid species in equilibria with solutions was crystalline (DsH remained crystalline upon dehydration. The different solid phases present in equilibria with solutions influenced solubility vs. pH of desipramine hydrochloride in phosphate buffers. They are also responsible for the difference between solubility profile of desipramine hydrochloride in phosphate buffers from that in the phosphate-free medium.
Given the solid state characterization in the present study, it is now clear that the earlier interpretation by Avdeef (2014b) of the desipramine hydrochloride behavior in 0.15 M phosphate buffer (Bergström et al., 2004) was based on an invalid assumption that the precipitate in the pH 7-9 region was the desipramine free base. It is now clear that the free base exists only above pH 9.5 in the phosphate buffer.
The [B] , [PO 4 3− ], and [H + ] roots of the above equations are solved using standard mathematical techniques (Avdeef, 2012) . K w and the ionization constants are generally provided as fixed parameters in the calculation. Those of standard buffers are coded internally, adjusted to the assay conditions of temperature and ionic strength.
If the concentration of the drug is above the intrinsic solubility and the pH of the solution is very alkaline, then Eq. (A.5) needs to be introduced into the calculation. The calculation becomes more complex, since one of the reactants loses its independence, and needs to be expressed in terms of the remaining reactants. One less mass balance equation needs to be explicitly considered in the solution for the roots. This procedure has been described in detail elsewhere (Avdeef, 2017 .6 ) and (A.7) would need to be considered in the further more complicated procedure. At very low pH, the possible role of the drug-chloride precipitate (Eq. (A.8)) is tested for. The program automatically checks to see if the solubility products are exceeded at a particular pH, and appropriate constraints are automatically applied. At any given pH, the program tests for any violations of the Gibbs Phase Rule. All such complicated equations are sorted out implicitly in the mass action algorithm of pDISOL-X, and their explicit derivations are not necessary for the computation.
